Recently, there has been a growing focus on investigating the influence of periodontitis on the aging population. There is epidemiological evidence that indicates periodontitis is associated with mortality, and it has been shown to accelerate the biological processes of aging. However, the precise mechanism by which periodontitis accelerates the process of the aging population remains to be elucidated. This paper reviews relevant research results and finds that periodontitis may be associated with accelerated aging and increased mortality through the following mechanisms: 1) the inflammatory mediators produced by periodontitis are released into the bloodstream and promote “inflammageing”, which accelerates aging through activation of the NF-κB signaling pathway and the senescence-associated secretory phenotype; 2) periodontal pathogens can promote the aging process in the following three ways: ① periodontal pathogens and bacterial products promote “inflammageing” through blood circulation, and they lead to abnormal changes in SIRT1 and mTOR, important aging markers in the blood, which induces mitochondrial dysfunction and accelerates aging; ② porphyromonas gingivalis overactivates the Akt/FoxO1 pathway to directly promote the aging of dendritic cells and produce exosomes that transmit and amplify paracrine immunosenescence; and ③ periodontal pathogens are ectopically colonized in the intestinal tract and lead to gut dysbiosis, thus indirectly accelerating the aging process.

Objective To investigate the MRI manifestations of ovarian serous surface papillary borderline tumor(SSPBT).Methods The data from 10 cases of ovarian SSPBT confirmed by surgical pathology were collected,with a median age of 28.5 years.Two radiologists analyzed the MRI manifestations and laboratory examination results of the lesions.Results Among the 10 patients,7 had bilateral ovarian involvement,with 14 lesions observed on MRI.All lesions were solid and cystic,12 lesions were adjacent to normal ovaries,12 lesions exhibited a flocculent or spongy appearance,and 10 lesions showed the"anemone sign".Contrast-enhanced scans revealed progressive moderate or marked enhancement,without lymphadenopathy or distant metastasis.Elevated serum CA125 levels were found in 8 patients.Conclusion Ovarian SSPBT have relatively characteristic imaging manifestations.Combining patient age,imaging manifestations,and laboratory examination results can often lead to an accurate diagnosis.

Objective To evaluate the clinical efficacy of Bushen Jianpi Formula(BSJPF)in treating type 2 diabetes mellitus(T2DM)complicated with non-alcoholic fatty liver disease(NAFLD)of spleen-kidney deficiency type.Methods Seventy-two patients with T2DM complicated with NAFLD of spleen-kidney deficiency type admitted to Clifford Hospital from June 2023 to September 2024 were randomized into treatment group(n=36,receiving lifestyle intervention+metformin+BSJPF)and control group(n=36,lifestyle intervention+metformin alone)for 12 weeks.TCM syndrome scores,liver function markers,ultrasonographic grading of fatty liver,glycolipid metabolic parameters were observed,and the clinical efficacy and safety were assessed.Results(1)Regarding dropouts,during the study,2 patients in the treatment group dropped out,while none occurred in the control group.Ultimately,34 patients in the treatment group and 36 in the control group completed efficacy evaluation.(2)In terms of clinical efficacy,after 12 weeks of treatment,the total effective rate was 88.24％(30/34)in the treatment group versus 66.67％(24/36)in the control group.Intergroup comparison(by chi-square test)showed significantly superior efficacy in the treatment group(P＜0.05).(3)For liver function indicators,after treatment,serum alanine aminotransferase(ALT),aspartate aminotransferase(AST),and γ-glutamyl transpeptidase(GGT)levels decreased significantly in both groups compared to those before treatment(P＜0.05),with substantially greater reduction in the treatment group(P＜0.05).(4)Regarding fatty liver ultrasound grading,both groups showed improvement after treatment(P＜0.05),with significantly greater enhancement in the treatment group(P＜0.05).(5)For glucose-lipid metabolism markers,both groups exhibited decreased fasting blood glucose(FBG),2-hour postprandial glucose(2hPG),glycated hemoglobin(HbA1c),fasting insulin(FINS),insulin resistance index(HOMA-IR),total cholesterol(TC),triglycerides(TG),and low-density lipoprotein cholesterol(LDL-C)levels(P＜0.05),with treatment group showing markedly greater reductions(P＜0.05);both groups demonstrated increased high-density lipoprotein cholesterol(HDL-C)levels(P＜0.05),with treatment group showing significantly greater elevation(P＜0.05).(6)In TCM syndrome score assessment,both groups showed reduced scores after treatment(P＜0.05),with treatment group demonstrating significantly greater improvement(P＜0.05).(7)Regarding safety,routine blood/urine/stool tests,renal function indicators,and electrocardiograms remained normal in both groups.The adverse reaction rate was 2.94％(1/34)in treatment group versus 5.56％(2/36)in control group,with no statistically significant difference between groups(P＞0.05).Conclusion BSJPF combined with metformin demonstrates superior efficacy to metformin alone for patients with T2DM complicated with NAFLD of spleen-kidney deficiency type.It is effective in relieving clinical symptoms,enhancing TCM syndrome efficacy,improving liver enzymes,fatty liver grading and insulin resistance,and regulating glycolipid metabolism.

Autism spectrum disorder(ASD)is a severe neurodevelopmental disorder with onset in child-hood,characterized by persistent social communication deficits and restricted,repetitive patterns of behavior.In recent years,its global prevalence has shown a continuous upward trend.However,there remains a lack of effective treatments capable of improving brain function in ASD.This article systematically reviews the mechanisms,clinical efficacy,and safety of HBOT in ASD,while exploring its potential therapeutic value.Research indicates that HBOT exerts its effects through the following mechanisms:enhancing plasma oxygen saturation,thereby improving oxygen supply to ischemic brain regions;inhibiting microglial activation,reducing pro-inflammatory cytokine levels;modulating gut microbiota homeostasis,restoring brain-gut axis dysfunction.Clinical studies demonstrate that when HBOT is combined with Applied Behavior Analysis(ABA),it significantly reduces behavioral scale scores in children with ASD while improving their social interaction,self-care abilities,and verbal communication.Additionally,HBOT positively regulates oxidative stress markers and enhances perfusion in specific brain regions.Regarding safety,strict adherence to operational protocols minimizes the risk of adverse effects(e.g.,baro-trauma).This review provides evidence-based support for the standardized application of HBOT in ASD.Future re-search should focus on optimizing treatment protocols(e.g.,pressure and oxygen concentration parameters)and evaluating long-term efficacy.

Objective To investigate the MRI manifestations of ovarian serous surface papillary borderline tumor(SSPBT).Methods The data from 10 cases of ovarian SSPBT confirmed by surgical pathology were collected,with a median age of 28.5 years.Two radiologists analyzed the MRI manifestations and laboratory examination results of the lesions.Results Among the 10 patients,7 had bilateral ovarian involvement,with 14 lesions observed on MRI.All lesions were solid and cystic,12 lesions were adjacent to normal ovaries,12 lesions exhibited a flocculent or spongy appearance,and 10 lesions showed the"anemone sign".Contrast-enhanced scans revealed progressive moderate or marked enhancement,without lymphadenopathy or distant metastasis.Elevated serum CA125 levels were found in 8 patients.Conclusion Ovarian SSPBT have relatively characteristic imaging manifestations.Combining patient age,imaging manifestations,and laboratory examination results can often lead to an accurate diagnosis.

Autism spectrum disorder(ASD)is a severe neurodevelopmental disorder with onset in child-hood,characterized by persistent social communication deficits and restricted,repetitive patterns of behavior.In recent years,its global prevalence has shown a continuous upward trend.However,there remains a lack of effective treatments capable of improving brain function in ASD.This article systematically reviews the mechanisms,clinical efficacy,and safety of HBOT in ASD,while exploring its potential therapeutic value.Research indicates that HBOT exerts its effects through the following mechanisms:enhancing plasma oxygen saturation,thereby improving oxygen supply to ischemic brain regions;inhibiting microglial activation,reducing pro-inflammatory cytokine levels;modulating gut microbiota homeostasis,restoring brain-gut axis dysfunction.Clinical studies demonstrate that when HBOT is combined with Applied Behavior Analysis(ABA),it significantly reduces behavioral scale scores in children with ASD while improving their social interaction,self-care abilities,and verbal communication.Additionally,HBOT positively regulates oxidative stress markers and enhances perfusion in specific brain regions.Regarding safety,strict adherence to operational protocols minimizes the risk of adverse effects(e.g.,baro-trauma).This review provides evidence-based support for the standardized application of HBOT in ASD.Future re-search should focus on optimizing treatment protocols(e.g.,pressure and oxygen concentration parameters)and evaluating long-term efficacy.

Objective:To analyze the gene mutation type and clinical phenotype of patients with PRRT2 mutation, and explore their relations with prognosis. Methods:A total of 18 patients with PRRT2 gene mutation (1 patient with novel mutation in PRRT2 gene, and 17 probands in 17 families with PRRT2 gene mutation) were enrolled in Department of Neurology, First Affiliated Hospital of Air Force Medical University from January 2018 to July 2023. Serum of the patients was collected for whole exon sequencing, and mutation sites and types of PRRT2 gene were analyzed. SWISS-MODEL website was used to predict the changes in protein structure caused by PRRT2 gene mutation. The relations of gene mutation type and clinical phenotype with prognosis of these patients were analyzed. Results:(1) All 18 patients with PRRT2 gene mutation were heterozygous mutation, including 12 frameshift mutations, 5 missense mutations, and 1 integer mutation. The clinical phenotype included benign familial infantile epilepsy (BFIE) in 5 patients, epilepsy in 6 patients, exercise-induced paroxysmal kinesigenic dyskinesia (PKD) in 5 patients, and infantile convulsion and choreoathetosis (ICCA) in 2 patients. A total of 8 mutation sites were found in 18 patients with PRRT2 gene mutation, of which 3 mutation sites have been reported, and 5 mutation sites have not been reported, including c.647(exon2)C>A, c.647(exon2)C>G, c.170(exon2)delC, c.981(exon3)C>G, and lossl(EXON: 2)(all). (2) Eighteen patients mainly accepted oxcarbazepine, levetiracetam, and sodium valproate in combination or monotherapy. Among them, 5 BFIE patients, 2 ICCA patients and 3 epilepsy patients were seizure-free after treatment. PKD patients did not respond well to oxcarbazepine. (3) Three frameshift mutations (mutation sites: c.649 [exon2]_c.650 [exon2] insC, c.640 [exon2]_c.641 [exon2] insC, and c.170 [exon2] delC) led to premature termination of protein translation, resulting in significant changes in protein structure. Four missense mutations (mutation sites: c.640[exo2]G>C, c.647[exon2]C>A, c.647[exon2]C>G, and c.981[exon3]C>G) had little effect on protein structure changes. No relation was found between changes of protein structure caused by different mutation types and prognosis. Conclusion:PRRT2 gene mutation patients with clinical phenotypes of BFIE and ICCA have good prognosis, but the mutation type is not related with the prognosis of patients.

Objective:To investigate the clinical, pathological and genetic characteristics of myopathy-type very long chain acyl-coenzyme A dehydrogenase deficiency (VLCADD).Methods:The detailed clinical data, muscle biopsy pathology and molecular results of 4 patients with genetically confirmed myopathy-type VLCADD admitted to Henan Provincial People′s Hospital and Xuanwu Hospital, Capital Medical University from June 2014 to November 2019 were retrospectively analyzed.Results:All of the 4 patients were late-onset myopathy-type VLCADD. The onset age ranged from 13 to 16 years, with a mean age of 14.5 years. The age at diagnosis ranged from 21 to 54 years, with a mean age of 42.5 years. The main clinical manifestation was repeated rhabdomyolysis, including myalgia, weakness and dark urine. Obvious somnolence was observerd in 1 patient. Muscle biopsy pathology revealed mild lipid accumulation, without vacuoles. Six ACADVL variations were detected in the 4 patients, including c.1283G>A (p.R428H), c.1532G>A (p.R511Q), c.833_835delAGA (p.K278del), c.1843C>T (p.R615 *), c.1748C>T (p.S583L) and c.1391C>T (p.T464I),among which c.1391C>T (p.T464I) was a novel variation, predicted to be likely pathogenic. Other 5 variations were reported pathogenic variations. Conclusions:Myopathy-type VLCADD is characterized by paroxysmal rhabdomyolysis and can be associated with somnolence. There is no specificity in muscle pathology. There are ACADVL variations, among which c.1391C>T is a novel variation.

Multiple sclerosis (MS) is an idiopathic inflammatory demyelinating diseases of the central nervous system, the underlying cause of which has not been cleared. Previous studies have shown that the pathogenesis of MS is related to the destruction of blood brain barrier, furthermore the drugs used to treat MS have a certain protective effect on the function of blood brain barrier. Therefore, this review combines the research progress at home and abroad to clarify the relationship between the blood brain barrier and MS in pathogenesis and treatment, proposing possible orientation of development.

Objective:To evaluate the efficacy and safety of fasudil on vasospasm caused by subarachnoid hemorrhage in elderly patients.Methods:A total of 100 elderly patients with subarachnoid hemorrhage admitted to our hospital from January 2015 to May 2018 were enrolled as research objects.They were randomly divided into the Fasudil group(n=50, receiving the Rho kinase inhibitor Fasudil therapy)and the Nimodipine group(n=50, receiving Nimodipine therapy). The cerebral vasospasm and cerebral infarction lesions, the ability of daily life, clinical prognostic score, the incidence of symptomatic cerebral vasospasm and adverse reactions during treatment were evaluated and compared between the two groups.Results:After treatment, the incidences of cerebral vasospasm and cerebral infarction in Fasudil group were 2.04%(1/49)and 6.12%(3/49), respectively, which were lower than those in the Nimodipine group[12.50%(6/48)and 20.83%(10/48), respectively]( χ2=6.134 and 6.794, P=0.047 and 0.033). The scores of daily living ability was better in the Fasudil group than in the Nimodipine group(16.09±1.06 vs.22.91±1.66, t=7.721, P=0.026). The incidence of adverse reactions was lower in the Fasudil group than in the Nimodipine group(4.08% or 2/49 vs.16.7% or 8/48, χ2=6.362, P=0.040). There was no statistically significant difference in the proportion of patients with good prognosis between Fasudil group and Nimodipine group. Conclusions:Rho kinase inhibitor Fasudil can effectively prevent and improve cerebral vasospasm caused by subarachnoid hemorrhage, which is beneficial for improving the clinical prognosis and quality of life of the elderly patients with subarachnoid hemorrhage.